Evaluation of STX-721 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Specific Mutations

The primary objective of this study is to evaluate the efficacy and safety of **STX-721** in participants with **locally advanced or metastatic non-small cell lung cancer** (NSCLC) harboring specific genetic mutations. This is clinically relevant as NSCLC is a prevalent form of lung cancer, and targeted therapies can potentially improve outcomes for patients with specific mutations. The study aims to provide insights into the therapeutic potential of STX-721, contributing to the development of personalized treatment strategies for this patient population.

The clinical trial involves a total of **97 participants** diagnosed with **Locally Advanced or Metastatic Non-Small Cell Lung Cancer**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the efficacy and safety of STX-721 in participants diagnosed with **locally advanced or metastatic non-small cell lung cancer**. The study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The trial is anticipated to commence recruitment on February 29, 2024, and is projected to conclude by June 1, 2027, encompassing a total duration of approximately three years and three months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation, including medical history, physical examination, and necessary laboratory tests. Following successful screening, participants will be randomly assigned to receive either the investigational product or a control. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health status, treatment adherence, and any adverse events. These visits will also include assessments to measure the primary and secondary endpoints of the trial.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, a final evaluation will be conducted to gather data on the long-term effects of the treatment. The expected length of participant involvement will vary depending on individual response and the overall study timeline but is generally expected to last until the trial's completion. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data while prioritizing participant safety and well-being.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The absence of these details suggests that the focus is primarily on the experimental medication, although further information would be required to confirm this aspect of the trial design.

Details regarding **participant compliance monitoring** and specific **dosing schedules** are not included in the provided data. This lack of information indicates that additional documentation would be necessary to fully understand the administration and monitoring protocols within the trial.

The clinical trial will assess efficacy through a structured evaluation process. The trial is scheduled to commence recruitment on February 29, 2024, with an estimated completion date of June 1, 2027. The trial is categorized under phase 7, indicating a specific stage in the clinical research process. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's effectiveness. The methodology for measuring efficacy will adhere to standard clinical trial protocols, ensuring the reliability and validity of the results. The trial's design will incorporate appropriate tools and instruments to facilitate accurate efficacy assessments, although these are not specified in the available data.